오성용 연구실은 동아대학교 의학과를 기반으로 혈액종양과 고형암을 아우르는 종양내과 임상연구를 수행하며, 림프종 및 다양한 암종의 예후인자 분석, 표적치료·면역항암제 병용전략 검증, 항암치료 부작용 관리, 첨단 면역세포치료 응용까지 포함하는 환자 중심의 정밀 항암치료 연구를 전개하고 있다.
1885P Pexa-vec (thymidine kinase-deactivated vaccinia virus plus GM-CSF) in combination with cemiplimab (REGN2810; ANTI-PD-1) for metastatic or unresectable renal cell carcinoma REN026: Results from a phase II study
Sun Young Rha, Woo Kyun Bae, Chung Hun Kim, Sung Yong Oh, Hyun Woo Lee, K. Park, Nataliya Mar, Ganessan Kichenadasse, Hong Koo Ha, Russell K. Pachynski, Inkeun Park, K.H. Park, Sihyun Kim, Edmund Folefac, Melissa Mathias, Frank Seebach, Mohammad Ali Shokrgozar, Lorena Carranza, S-H. Beom, Jaime R. Merchan
1523P Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC)
Mustapha Tehfé, J. Lee, Sun Young Rha, Yoshiaki Nakamura, Josep Tabernero, Kohei Shitara, D-Y. Oh, Jennifer R. Eads, J. Marshall, Zev A. Wainberg, Kyung-Woo Lee, Y-K. Kang, C-Y. Liao, Sung Yong Oh, Kun‐Huei Yeh, Donald Richards, Michelle Ubowski, K. Zhao, S. Bhaumik, John H. Strickler